Oric Pharmaceuticals, Inc. ORIC 深 滬
已收盤 02-06 16:00:00 美东时间
10.42
+0.460
+4.62%
華盛通- 最 高10.66
- 今 開10.43
- 成交量 198.74万股
- 最 低 9.99
- 昨 收 9.96
- 總市值 10.15亿
- 52周最高 14.93
- 市盈率 靜 --
- 換手率 2.04%
- 52周最低 3.8951
- 委 比 78.56%
- 總股本 9738.93万
- 歷史最高 40.81
- 量 比 1.36
- 振 幅 6.73%
- 歷史最低 2.36
- 每 手 1
- 風險率 2.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 算力基建再提速！Galaxy Digital 涨超37%，获批电力容量翻番；创新药企IBRX大涨近137%
算力基建再提速！Galaxy Digital 周涨超37%，获批电力容量翻番；创新药企IBRX周涨近137%，在研创新药获批上市>>
01-17 10:31
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Piper Sandler Initiates Coverage On ORIC Pharmaceuticals with Overweight Rating, Announces Price Target of $22
Piper Sandler analyst Kelsey Goodwin initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight rating and announces Price Target of $22.
01-07 21:04
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI
Evercore ISI analyst Cory Kasimov maintained a Buy rating on Oric Pharmaceutica...
2025-12-23 16:26
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price target.
2025-12-08 22:08
Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results
Oric Pharmaceuticals ( ($ORIC) ) has issued an update. On December 6, 2025, Ori...
2025-12-08 19:52
ORIC Pharmaceuticals Announces Poster Presentation From Phase 1b Study Of Enozertinib At ESMO Asia Congress 2025
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation highlighting data
2025-12-01 21:06
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
